$70M Credit Facility Secured as TELA Bio Reports 18% Q4 Revenue Growth, Targets Profitability
TELA sits 16% above its 52-week low of $0.667 on elevated volume (2.1× avg).
Summary
TELA Bio reported robust fourth-quarter 2025 financial results, with revenue increasing 18% to $20.9 million, contributing to a full-year revenue of $80.3 million, up 16% from 2024. The company also announced securing a significant $70.0 million credit facility from Perceptive Advisors, with an initial $60.0 million drawn. This financing is highly material, especially following the recent Nasdaq deficiency letter regarding the company's minimum bid price. The CEO's statement about achieving profitability without needing to raise additional capital directly addresses dilution concerns and provides a clearer path for the company to meet listing requirements. Investors will closely watch the company's execution on its 2026 revenue guidance of at least 8% growth and its progress towards sustainable profitability.
At the time of this announcement, TELA was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.9M. The 52-week trading range was $0.67 to $2.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.